Marine Compounds Will Transform Personalized Cancer Treatment Globally
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
20 Jul 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
€118.00
29.9% undervalued intrinsic discount15 Aug
€82.70
1Y
124.9%7D
4.6%